CASI Pharmaceuticals (CASIF) Income from Non-Controlling Interests (2022 - 2023)
CASI Pharmaceuticals (CASIF) reported Income from Non-Controlling Interests of -$742000.0 for Q4 2023, up 89.46% on a YoY basis from -$391648.2 in Q4 2022, and down 23.67% quarter-over-quarter from -$600000.0 in Q3 2023.
CASI Pharmaceuticals (CASIF) Income from Non-Controlling Interests (2022 - 2023) Analysis & Trends
CASI Pharmaceuticals has reported Income from Non-Controlling Interests for 2 years, with the latest figure at -$742000.0 in Q4 2023.
- For the quarter ending Q4 2023, Income from Non-Controlling Interests rose 89.46% year-over-year to -$742000.0; the trailing twelve-month figure through Dec 2023 stood at -$2.6 million (up 70.23% YoY), and the FY2023 full-year result was -$2.6 million, up 70.23% from the prior year.
- Income from Non-Controlling Interests for Q4 2023 stood at -$742000.0, down from -$600000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$417000.0 in Q1 2022, with the low at -$7.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | - |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -742,000.00 |
| Sep 30, 2023 | -600,000.00 |
| Jun 30, 2023 | -593,000.00 |
| Mar 31, 2023 | -667,000.00 |
| Dec 31, 2022 | -7.04 Mn |
| Sep 30, 2022 | -738,000.00 |
| Jun 30, 2022 | -548,000.00 |
| Mar 31, 2022 | -417,000.00 |